Squarepoint Ops LLC Acquires Shares of 17,242 LivaNova PLC $LIVN

Key Points

• Squarepoint Ops LLC acquired 17,242 LivaNova shares worth approximately $1.42 million during the second quarter. Institutional investors collectively own 97.64% of the company.
• Analyst sentiment remains favorable, with six Buy ratings and five Holds producing a “Moderate Buy” consensus and an average price target of $84.12.
• LivaNova reported quarterly EPS of $1.26, exceeding estimates by $0.17, while revenue rose 10.8% year over year to $390.59 million. Shares opened at $78.51, near the upper end of their 52-week range.

Squarepoint Ops LLC acquired a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 17,242 shares of the company's stock, valued at approximately $1,418,000.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Allworth Financial LP grew its stake in shares of LivaNova by 93.5% in the second quarter. Allworth Financial LP now owns 298 shares of the company's stock valued at $25,000 after buying an additional 144 shares in the last quarter. Hantz Financial Services Inc. lifted its position in LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company's stock worth $27,000 after acquiring an additional 267 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in LivaNova in the 2nd quarter worth approximately $37,000. Covestor Ltd boosted its holdings in LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company's stock worth $46,000 after acquiring an additional 392 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in LivaNova by 63.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 797 shares of the company's stock worth $49,000 after acquiring an additional 308 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on LIVN. Piper Sandler reiterated an "overweight" rating and set a $90.00 price objective (up from $87.00) on shares of LivaNova in a research note on Wednesday, September 2nd. Zacks Research downgraded shares of LivaNova from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. Mizuho raised their price target on shares of LivaNova from $90.00 to $95.00 and gave the company an "outperform" rating in a report on Wednesday, July 15th. KeyCorp lifted their price target on shares of LivaNova from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Monday, June 22nd. Finally, Freedom Capital upgraded shares of LivaNova to a "hold" rating in a report on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $84.12.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $78.51 on Thursday. LivaNova PLC has a fifty-two week low of $48.82 and a fifty-two week high of $85.76. The business has a 50 day moving average price of $80.12 and a two-hundred day moving average price of $73.55. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The firm has a market cap of $4.33 billion, a PE ratio of 23.23 and a beta of 0.87.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.17. The company had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.LivaNova's revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.05 EPS. Sell-side analysts expect that LivaNova PLC will post 3.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the completion of the sale, the director owned 7,488 shares in the company, valued at approximately $609,672.96. The trade was a 23.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Francesco Bianchi sold 3,500 shares of the company's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the completion of the sale, the director directly owned 4,434 shares in the company, valued at $345,896.34. This represents a 44.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 7,450 shares of company stock valued at $591,839. Insiders own 0.35% of the company's stock.

About LivaNova

LivaNova PLC NASDAQ: LIVN is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.

LivaNova's Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.